Tuesday, March 17, 2026

DDM Immune Prep Delivers 100% Survival Against Drug-Resistant Bacteria and Flu in Pre-Exposure Tests

Researchers develop a novel infection-prevention strategy using DDM, enhancing immune response against antibiotic-resistant pathogens.

The Astronomical Salaries of NVIDIA Employees

According to a report by the Wall...

North Korea Upgrades Airport Near Mount Paekdu as Tourism Push Gains Momentum

North Korea is upgrading Samjiyon Airport for international tourism, aiming to boost access to Mount Paekdu and enhance tourism infrastructure.

Tag: Eli Lilly

North KoreaKoreaKimMilitarySouth KoreaAIrelationsmarketInternational

Samsung Biologics Partners with Eli Lilly: How This Open Innovation Hub Will Transform K-Bio by 2027

Samsung Biologics partners with Eli Lilly to create a biotech innovation hub in Korea, enhancing growth opportunities for local firms.

South Korea’s Pharmaceutical Future: 500 Million USD Investment from Eli Lilly to Boost K-Bio Innovation

South Korea partners with Eli Lilly to boost biotech and pharma industries, investing $500M to enhance innovation and healthcare access.

Celltrion’s Strategic Move: How Local Production in the U.S. Can Mitigate Tariff Risks

Celltrion outlines its Branchburg facility's operations and plans to mitigate tariff risks by establishing local production and a supply system.

Eli Lilly vs. Novo Nordisk: A $1.2 Billion Bet Reveals Two Very Different Futures for Obesity Drugs

Eli Lilly and Novo Nordisk are pursuing different strategies in the obesity treatment market, focusing on expansion versus core strengths.

Nvidia and Eli Lilly: How AI is Revolutionizing Drug Development in 2026

Nvidia partners with Eli Lilly to enhance AI in drug development, aiming to revolutionize the biotech industry.

Rising Use of GLP-1 Drugs May Be Linked to Rare Pancreatitis Cases, Study Finds

Reports of acute pancreatitis linked to GLP-1 diabetes drugs surge in the UK, prompting investigations and conflicting academic findings.

Ozempic Maker Swaps CEO, Bets $2.2B on New Obesity Drug Fight

Novo Nordisk's leadership change aims to reclaim its obesity treatment market share amid competition from Eli Lilly's Mounjaro.

New Study: Mounjaro Helps Users Drop Over 50 Pounds

Eli Lilly's Mounjaro leads U.S. obesity drug market, outperforming semaglutide in weight loss efficacy and safety.

Novo Nordisk Pushes for First Oral Obesity Drug Approval

Novo Nordisk seeks FDA approval for oral Wegovy, potentially the first oral obesity treatment, amid competition with Eli Lilly.

Eli Lilly’s Oral GLP-1 Shows 7.9% Weight Loss in Type 2 Diabetes Trial

Eli Lilly's orforglipron shows promise in Phase 3 trials for diabetes and obesity, offering an oral alternative to injectables.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.